[The Usefulness of RFA as a Conversion Therapy after Molecular Targeted Therapy for Advanced Hepatocellular Carcinoma-A Case of Long-Term Survival with Multidisciplinary Treatment]

Gan To Kagaku Ryoho. 2023 Dec;50(13):1928-1930.
[Article in Japanese]

Abstract

In this study, we report a case in which molecular-targeted agents have been shown to be effective in the treatment of unresectable hepatocellular carcinoma(HCC), which has enabled a radical treatment, conversion therapy, and long-term survival with multimodality treatment including RFA. Case: A 61-year-old male, abdominal ultrasonography revealed a large liver tumor and multiple lesions mainly in the right lobe of the liver. He was diagnosed as having unresectable HCC, and treatment with sorafenib was initiated. After treatment, the tumor was clearly reduced in size and the lung metastases disappeared. Five years later, recurrence was observed at the treated site of S7/8, and RFA was performed again after TACE. The patient has survived for 8 years without recurrence.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Carcinoma, Hepatocellular* / drug therapy
  • Carcinoma, Hepatocellular* / surgery
  • Catheter Ablation*
  • Chemoembolization, Therapeutic*
  • Combined Modality Therapy
  • Humans
  • Liver Neoplasms* / drug therapy
  • Liver Neoplasms* / surgery
  • Male
  • Middle Aged
  • Molecular Targeted Therapy
  • Sorafenib
  • Treatment Outcome

Substances

  • Sorafenib